Publications

Journal Articles and Reviews

Colom-Cadena M, Toombs J, Simzer E, Holt K, McGeachan R, et al. Transmembrane protein 97 is a potential synaptic amyloid beta receptor in human Alzheimer’s disease. Acta Neuropathol 147, 32 (2024).
van Dyck, C.H., Mecca, A.P., O’Dell, R.S. et al. A pilot study to evaluate the effect of CT1812 treatment on synaptic density and other biomarkers in Alzheimer’s disease. Alz Res Therapy 16, 20 (2024).
Lizama BN, Kahle J, Catalano SM, et al. Sigma-2 Receptors—From Basic Biology to Therapeutic Target: A Focus on Age-Related Degenerative Diseases. Int. J. Mol. Sci. 2023, 24(7), 6251.
LaBarbera KM, Limegrover C, Rehak C, et al. Modeling the mature CNS: A predictive screening platform for neurodegenerative disease drug discovery. J Neurosci Methods. 2021 Jul 1;358:109180.
Rishton GM, Look GC, Ni Z-J, et al. Discovery of Investigational Drug CT1812, an Antagonist of the Sigma-2 Receptor Complex for Alzheimer’s Disease. ACS Med Chem Lett. 2021 Aug 9;12(9):1389-1395.
Izzo NJ, Yuede CM, LaBarbera KM, et al. Preclinical and clinical biomarker studies of CT1812: A novel approach to Alzheimer’s disease modification. Alzheimer’s Dement. 2021 Aug; 17(8):1365-1382
Izzo NJ, Colom-Cadena M, Riad AA, et al. Proceedings from the Fourth International Symposium on σ-2 Receptors: Role in Health and Disease. 7(6) ENEURO .0317-20.2020 1–7
Limegrover, CS, LeVine, H, III, Izzo, NJ, et al. Alzheimer’s Protection Effect of A673T Mutation May Be Driven by Lower Aβ Oligomer Binding Affinity. J Neurochem. 2020; 00: 1–15
Colom-Cadena M, Spires-Jones T, Zetterberg H, et al. The clinical promise of biomarkers of synapse damage or loss in Alzheimer’s disease. Alz Res Therapy 12, 21 (2020)

Medical and Scientific Meeting Presentations

Reaver A, Lizama BN, Caggiano AO, Hamby ME. Differentiated retinal pigment epithelial cells as a model for uncovering sigma-2 receptor functions and novel therapeutics for dry AMD. Poster presented at 2024 Association for Research in Vision & Ophthalmology.
Di Caro V, Pandey K, Cho E, et al. Identification of New Pharmacodynamic Biomarkers of CT1812 that Correlate with Favorable Functional Connectivity of the Brain. e-Poster presented at: AD/PD™ 2024 Alzheimer’s & Parkinson’s Diseases Conference; Lisbon, Portugal.
Lizama B, Duong D, Pandey K, et al. Plasma Proteomic Analysis from Alzheimer’s Patients in SPARC Clinical Trial to Identify Pharmacodynamic Biomarkers of the S2R Modulator CT1812. Poster presented at: AD/PD™ 2024 Alzheimer’s & Parkinson’s Diseases Conference; Lisbon, Portugal.
Di Caro V, Pandey K, Duong D, et al. Analysis of CSF Samples from a Phase 2 Clinical Trial in Alzheimer’s Patients Show that CT1812 can Modulate α-synuclein. Poster presented at: AD/PD™ 2024 Alzheimer’s & Parkinson’s Diseases Conference; Lisbon, Portugal.
Caldwell J, Cho E, Knezovich N, Caggiano AO, Di Caro V, Hamby ME (2023 November). A transcriptomic analysis to investigate the role of sigma-2 receptor modulators CT1812 and CT2168 in a mouse model of Alzheimer’s disease. Poster presented at: Society for Neuroscience (SfN) annual meeting; Washington DC.
Cho E, Caldwell J, Pandey K, Duong DM, Seyfried NT, Caggiano AO, Di Caro V, Hamby ME (2023 November). A proteomic analysis to elucidate the role of sigma-2 receptor modulators CT1812 and CT2168 in a mouse model of Alzheimer’s disease. Poster presented at: Society for Neuroscience (SfN) annual meeting; Washington DC.
Reaver AJ, Lizama BN, Pandey K, Duong DM, Seyfried NT, Caggiano AO, Hamby ME (2023 November). Exploratory omics study reveals potential roles of sigma-2 receptor modulators in AAV1/2A53T-aSyn rat model of Parkinson’s disease. Poster presented at: Society for Neuroscience (SfN) annual meeting; Washington DC.
Lizama BN, Reaver AJ, Pandey K, Duong DM, Seyfried NT, Caggiano AO, Hamby ME (2023 November). Unbiased proteomic and transcriptomic analysis of Sigma-2 receptor modulation in an in vivo model of synucleinopathy. Poster presented at: Society for Neuroscience (SfN) annual meeting; Washington DC.
Di Caro V, Pandey K, Lizama B, Cho E, Duong D, De Haan W, Grundman M, Seyfried N, Caggiano AO, Vijverberg E, Hamby ME (2023 October). Proteomic Analysis in a Phase 2 Clinical Trial Studying CT1812 to Identify CSF and Plasma Pharmacodynamic Biomarkers and Molecular Correlates of EEG in Alzheimer’s Patients. Poster presented at: Clinical Trials on Alzheimer’s Disease (CTAD); Boston, Massachusetts.
Lizama B, Cho E, Duong D, Pandey K, Williams C, Caggiano AO, Seyfried N, Di Caro V, Hamby ME (2023 October). Proteomic Analysis of Plasma in a Phase 2 Clinical Trial in Alzheimer’s Patients to Identify Pharmacodynamic Biomarkers of the S2R Modulator CT1812. Poster presented at: Clinical Trials on Alzheimer’s Disease (CTAD); Boston, Massachusetts.
De Haan W, Caggiano AO, Scheltens P, Grundman M, Scheijbeler E, Hamby ME, Vijverberg E (2023 October). A Pilot Electroencephalography (EEG) Study to Evaluate the Effect of CT1812 Treatment on Synaptic Activity in Subjects with Mild to Moderate Alzheimer’s Disease. Poster presented at: Clinical Trials on Alzheimer’s Disease (CTAD); Boston, Massachusetts.
van Dyck CH, Raman R, Donohue MC, Rissman RA, Rafii MS, Hamby ME, Grundman M, Caggiano AO, Aisen PS (2023 October). CT1812 START Study Design: Anti-Aβ Monoclonal Antibodies as Background Therapy. Oral presentation at: 2023 Clinical Trials on Alzheimer’s Disease (CTAD); Boston, Massachusetts.
Di Caro V, Cho E, Caldwell J, Pandey K, Duong DM, Seyfried NT, Caggiano AO, Hamby ME (2023 July). Brain transcriptomic and proteomic analyses in an in vivo AD model further elucidate the role of the sigma-2 receptor modulator CT1812 in Alzheimer’s disease. Oral presentation at: 2023 Alzheimer’s Association’s International Conference (AAIC); Amsterdam, The Netherlands.
Lizama B, Waybright L, Malagise E, Watto E, Caggiano AO, Hamby ME. Unbiased Transcriptomic Analysis of the sigma-2 Modulator, CT1812 in Cell-based Models of Dry Age-related Macular Degeneration. Poster presented at: 2023 Association for Research in Vision & Ophthalmology
Pandey K, Duong D, Waybright L, Lizama B, Mecca A, van Dyck C, Grundman M, Blennow K, Zetterberg H, Caggiano AO, Seyfried N, Hamby ME​ Pharmacodynamic Effects of the S2R Modulator CT1812 in Alzheimer’s Disease (AD) Patients Observed in a Meta-analysis of CSF Proteomes from SPARC and SHINE Part A. Poster presented at: AD/PD™ 2023 International Conference on Alzheimer’s and Parkinson’s Diseases
Galvin JE, Tolea MI, Hamby ME, Grundman M, Caggiano AO. A Randomized, Double-blind, Placebo-controlled, Phase 2, Six-month Study to Evaluate the Safety, Tolerability and Exploratory Efficacy of CT1812 in Participants with Mild-to-Moderate Dementia with Lewy Bodies. Poster presented at: 2022 Clinical Trials on Alzheimer’s Disease Congress; San Francisco, CA.  
Pandey K, Waybright L, Duong DM, Malagise E, Blennow K, Zetterberg H, Mecca AP, van Dyck CH, Caggiano AO, Seyfried NT, Hamby ME (2022 August). CSF Proteomics Biomarker Analysis from the SPARC Clinical Trial: to Assess the Effect of the Sigma-2 Receptor (S2R) Modulator CT1812 in Alzheimer’s Disease Patients. Oral presentation at: 2022 Alzheimer’s Association’s International Conference (AAIC); San Diego, CA.
Malagise E, Keeling E, Knezovich N, Waybright L, Watto E, Caggiano AO, Ratnayaka A, Hamby ME (2022 May). Sigma-2 receptor modulators rescue POS trafficking deficits in RPE cell-based models of dry AMD. Poster presented at: 2022 Annual Meeting of the Association for Research in Vision and Ophthalmology (ARVO); Denver, CO.
Izzo NJ, LaBarbera KM, Yuede CM, Waybright L, Yurko R, Sheline YI, Edwards HM, Gardiner WD, Blennow K, Zetterberg H, Hanson AB, Davis CS, Guttendorf RJ, Schneider LS, DeKosky S, Caggiano AO, Grundman M, Catalano SM, Cirrito JR, Hamby ME (2022 March). Experimental Therapeutic CT1812 Demonstrates Target Engagement in a Phase 1b Clinical Trial to Measure Displacement of Aβ Oligomers Into CSF. Poster presented at: AD/PD™ 2022 International Conference on Alzheimer’s and Parkinson’s Diseases; Barcelona, Spain.
Seyfried N, Waybright L, Duong D, Malagise E, Pandey K, Williams C, Dammer E, Ping L, Blennow K, Zetterberg H, Lah J, Levey A, Ricciardi L, Caggiano AO, Hamby ME (March 2022). Proteomic Analysis of CSF in a Phase 2 Clinical Trial for AD to Identify Pharmacodynamic Biomarkers of the S2R Modulator CT1812. Poster presented at: AD/PD™ 2022 International Conference on Alzheimer’s and Parkinson’s Diseases; Barcelona, Spain.
Foundational Principles of Neuroscience: Genetic Basis of Alzheimer’s Disease: Synapse Loss Correlates to Cognitive Deficit: Monomers, Oligomers, Fibrils and Plaques – the Aβ Equilibrium: Aβ Accumulates and Self-Associates into Oligomers: Aβ Oligomers Bind to a Receptor Complex on Synapses: Bound Aβ Oligomers are Toxic to Synapses: Sigma-2 Receptor Complex Biology and Role in Disease: Biomarkers of Disease and Target Engagement:
AMD Rationale:
Scroll to Top

You are now leaving the Cognition Therapeutics website

Cognition Therapeutics assumes no responsibility for the content of third-party website. Neither does Cognition control, endorse or guarantee any aspect of your use of third-party sites. We encourage you to read and evaluate terms of use, privacy and other policies of the destination site as they may differ from Cognition’s policies.

Thank you for your interest in Cognition’s publications. A PDF of the poster you are interested in will be made available in accordance with the congress’ embargo policy. Please check back soon. 

You are now leaving the Cognition Therapeutics website

Cognition Therapeutics assumes no responsibility for the content of third-party website. Neither does Cognition control, endorse or guarantee any aspect of your use of third-party sites. We encourage you to read and evaluate terms of use, privacy and other policies of the destination site as they may differ from Cognition’s policies.

You are now leaving the Cognition Therapeutics website

Cognition Therapeutics assumes no responsibility for the content of third-party website. Neither does Cognition control, endorse or guarantee any aspect of your use of third-party sites. We encourage you to read and evaluate terms of use, privacy and other policies of the destination site as they may differ from Cognition’s policies.

You are now leaving the Cognition Therapeutics website

Cognition Therapeutics assumes no responsibility for the content of third-party website. Neither does Cognition control, endorse or guarantee any aspect of your use of third-party sites. We encourage you to read and evaluate terms of use, privacy and other policies of the destination site as they may differ from Cognition’s policies.

You are now leaving the Cognition Therapeutics website

Cognition Therapeutics assumes no responsibility for the content of third-party website. Neither does Cognition control, endorse or guarantee any aspect of your use of third-party sites. We encourage you to read and evaluate terms of use, privacy and other policies of the destination site as they may differ from Cognition’s policies.

You are now leaving the Cognition Therapeutics website

Cognition Therapeutics assumes no responsibility for the content of third-party website. Neither does Cognition control, endorse or guarantee any aspect of your use of third-party sites. We encourage you to read and evaluate terms of use, privacy and other policies of the destination site as they may differ from Cognition’s policies.